Back to News
Market Impact: 0.2
Polyrizon Reports Enrollment Of First Patient In Trial For Allergy Nasal Spray NASARIX
Source: Nasdaq
Healthcare & Biotech
Polyrizon enrolled the first patient in its clinical study of NASARIX for seasonal allergic rhinitis. The milestone advances the clinical-stage biotech program, but the article provides no efficacy, safety, timeline, or financial data.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
PLRZ0.55
More News
- Trump admin says it will save $2.2 billion by kicking off 760,000 Affordable Care Act enrollees over fraud claims
- US and Iran Sit Down for Talks at the UN: Evening Briefing Americas
- In Senegal, a mother’s ordeal exposes a health system under strain
- Halozyme Therapeutics completes $1.5 billion convertible notes offering
- Trump administration removes around 760,000 Obamacare enrollments, alleging fraud
- Dozens of people sue GLP-1 drug companies over alleged vision loss